83 related articles for article (PubMed ID: 3701643)
1. Pharmacokinetics of melphalan in isolated perfusion of the limbs.
Benckhuijsen C; Varossieau FJ; Hart AA; Wieberdink J; Noordhoek J
J Pharmacol Exp Ther; 1986 May; 237(2):583-8. PubMed ID: 3701643
[TBL] [Abstract][Full Text] [Related]
2. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics.
Benckhuijsen C; Kroon BB; van Geel AN; Wieberdink J
Eur J Surg Oncol; 1988 Apr; 14(2):157-63. PubMed ID: 3360157
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities.
Briele HA; Djuric M; Jung DT; Mortell T; Patel MK; Das Gupta TK
Cancer Res; 1985 Apr; 45(4):1885-9. PubMed ID: 3978649
[TBL] [Abstract][Full Text] [Related]
4. A simple and accurate new method for cytostatics dosimetry in isolation perfusion of the limbs based on exchangeable blood volume determination.
Lejeune FJ; Ghanem GE
Cancer Res; 1987 Jan; 47(2):639-43. PubMed ID: 3791248
[TBL] [Abstract][Full Text] [Related]
5. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies.
Thompson JF; Siebert GA; Anissimov YG; Smithers BM; Doubrovsky A; Anderson CD; Roberts MS
Br J Cancer; 2001 Jul; 85(2):157-65. PubMed ID: 11461070
[TBL] [Abstract][Full Text] [Related]
6. Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb.
Wu ZY; Smithers BM; Roberts MS
J Pharmacol Exp Ther; 1997 Sep; 282(3):1131-8. PubMed ID: 9316818
[TBL] [Abstract][Full Text] [Related]
7. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor.
Fraker DL; Alexander HR; Andrich M; Rosenberg SA
Cancer J Sci Am; 1995; 1(2):122-30. PubMed ID: 9166465
[TBL] [Abstract][Full Text] [Related]
8. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of isolated lung perfusion with melphalan for resectable pulmonary metastases, a phase I and extension trial.
Grootenboers MJ; Hendriks JM; van Boven WJ; Knibbe CA; van Putte B; Stockman B; De Bruijn E; Vermorken JB; Van Schil PE; Schramel FM
J Surg Oncol; 2007 Dec; 96(7):583-9. PubMed ID: 17999399
[TBL] [Abstract][Full Text] [Related]
10. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
11. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
12. Is there an indication for a double perfusion schedule with melphalan for patients with recurrent melanoma of the limbs?
Klaase JM; Kroon BB; van Geel AN; Eggermont AM; Franklin HR; van Dongen JA
Melanoma Res; 1994 Mar; 4 Suppl 1():13-6. PubMed ID: 8038589
[TBL] [Abstract][Full Text] [Related]
13. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion.
Di Filippo F; Giacomini P; Rossi CR; Santinami M; Anzà M; Garinei R; Perri P; Botti C; Di Angelo P; Sofra C; Pasqualoni R; Sperduti I; Cavaliere F; Di Filippo S; Corrias F; Armenti A; Ferraresi V; Ginebri A
In Vivo; 2009; 23(2):347-52. PubMed ID: 19414425
[TBL] [Abstract][Full Text] [Related]
15. Can tissue drug concentrations be monitored by microdialysis during or after isolated limb perfusion for melanoma treatment?
Wu ZY; Smithers BM; Anderson C; Roberts MS
Melanoma Res; 2000 Feb; 10(1):47-54. PubMed ID: 10711640
[TBL] [Abstract][Full Text] [Related]
16. The role of hyperthermia in regional alkylating agent chemotherapy.
Abdel-Wahab OI; Grubbs E; Viglianti BL; Cheng TY; Ueno T; Ko S; Rabbani Z; Curtis S; Pruitt SK; Dewhirst MW; Tyler DS
Clin Cancer Res; 2004 Sep; 10(17):5919-29. PubMed ID: 15355925
[TBL] [Abstract][Full Text] [Related]
17. Melphalan monitoring during hyperthermic perfusion of isolated limb for melanoma: pharmacokinetic study and 99mTc-albumin microcolloid technique.
Cattel L; Buffa E; De Simone M; Cesana P; Novello S; Dosio F; Ceruti M
Anticancer Res; 2001; 21(3C):2243-8. PubMed ID: 11501854
[TBL] [Abstract][Full Text] [Related]
18. Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system.
Zwaveling JH; Maring JK; Mulder AB; Bom VJ; van Ginkel RJ; Schraffordt Koops H; Girbes AR; Hoekstra HJ; van der Meer J
Cancer Res; 1996 Sep; 56(17):3948-53. PubMed ID: 8752162
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of melphalan in isolated limb perfusion.
Norda A; Loos U; Sastry M; Goehl J; Hohenberger W
Cancer Chemother Pharmacol; 1999; 43(1):35-42. PubMed ID: 9923539
[TBL] [Abstract][Full Text] [Related]
20. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan.
Vaglini M; Santinami M; Manzi R; Inglese MG; Santoro N; Persiani L; Belli F
Melanoma Res; 1994 Mar; 4 Suppl 1():35-8. PubMed ID: 8038594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
